Stockscreener 앱 받기
7.69
3.22%
0.24
시장 영업 전:
7.69
Vir Biotechnology Inc 주식(VIR)의 최신 뉴스
Vir Biotechnology, Inc. (VIR) Stock Analysis: A Biotech with a Promising 131% Upside Potential - DirectorsTalk Interviews
Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial - Yahoo Finance
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trading Recap: What makes Stran Company Inc Equity Warrant stock attractive today2025 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Update: Can Vir Biotechnology Inc outperform under higher oil pricesJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9%Should You Buy? - MarketBeat
Aug Macro: Can BankUnited Inc outperform under higher oil prices2025 Risk Factors & Daily Market Momentum Tracking - baoquankhu1.vn
Aug Final Week: Is Vir Biotechnology Inc a strong growth stock2025 Investor Takeaways & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (VIR) Advances in Hepatitis Delta Treatment - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Trading 7.3% HigherWhat's Next? - MarketBeat
Vir Biotechnology shows positive results in hepatitis delta trial - Traders Union
Vir Biotechnology (VIR) Reports Positive Trial Results in Hepati - GuruFocus
Vir Biotechnology reports promising results for hepatitis delta therapy By Investing.com - Investing.com Nigeria
Vir Biotechnology reports promising results for hepatitis delta therapy - Investing.com
Vir Biotechnology reports positive Phase 2 hepatitis delta data, outlines 2026 clinical milestones - MSN
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - BioSpace
Vir Biotechnology advances hepatitis delta program and cash runway - TipRanks
Vir Biotechnology provides updates on chronic hepatitis Delta and oncology programs and upcoming 2026 clinical milestones - marketscreener.com
Vir Biotechnology reports positive hepatitis delta trial data - StreetInsider
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones - TradingView — Track All Markets
How Vir Biotechnology Inc. stock performs after earnings2025 Biggest Moves & Verified Momentum Stock Watchlist - ulpravda.ru
Is Vir Biotechnology Inc. stock a safe haven assetWeekly Profit Analysis & Weekly Stock Breakout Alerts - Улправда
Will Vir Biotechnology Inc. stock keep outperforming rivalsJuly 2025 Big Picture & Low Risk Investment Opportunities - Улправда
Profit Recap: Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Summary Report & Free High Accuracy Swing Entry Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - Bộ Nội Vụ
What is HC Wainwright's Forecast for VIR FY2025 Earnings? - MarketBeat
Aug PreEarnings: Why Vir Biotechnology Inc stock remains resilientJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4%Here's What Happened - MarketBeat
VIR: HC Wainwright & Co. Reiterates 'Buy' Rating with $15 Price Target | VIR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
With Vir Biotechnology Stock Sliding, Have You Assessed The Risk? - Trefis
Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
EV Market: Can Vir Biotechnology Inc. stock resist market sell offsEarnings Recap Summary & Precise Buy Zone Tips - Улправда
Aug Swings: Will Vir Biotechnology Inc stock benefit from M A activityOptions Play & Weekly Sector Rotation Insights - moha.gov.vn
Why analysts remain bullish on Vir Biotechnology Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Is Vir Biotechnology Inc. stock a buy for dividend growthJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Can Vir Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - DonanımHaber
Will Vir Biotechnology Inc. stock outperform value stocks2025 Short Interest & Weekly High Return Stock Opportunities - DonanımHaber
Published on: 2025-12-19 13:20:41 - Улправда
2.09%
0.48%
자본화:
|
볼륨(24시간):